Abstracts Archive - Page 557 of 2607 - ACR Meeting Abstracts

Abstract Number: 1105 • ACR Convergence 2022
TeleRheumatology in the COVID Era: Preparing Trainees for Virtual Care Using an Observed Clinical Skills Exam (OSCE)
Iyer Priyanka¹ and Chow Emilie², ¹UC Irvine Medical Center, Orange, ²UC Irvine Medical Center, Orange
Background/Purpose: The SARS-COVID-19 pandemic has had a substantial, predominantly negative impact on rheumatology training and on overall trainee well-being. During the early stages of the…
Abstract Number: 1104 • ACR Convergence 2022
Teaching Trainees How to Think: A Quality Improvement Project to Increase Recognition of Cognitive Errors in Rheumatology Fellowship
Megan Milne¹, Rebecca Sadun², Lena Eder³, Sonali Bracken⁴, Poorva Apte², Catherine Sims², Nathaniel Harris⁴, Amanda Eudy⁵ and david leverenz⁶, ¹Duke University Medical Center Division of Rheumatology and Immunology, Durham, NC, ²Duke University, Durham, NC, ³Duke University Hospital, Durham, NC, ⁴Duke University Medical Center, Durham, NC, ⁵Duke University, Raleigh, NC, ⁶Duke University School of Medicine, Durham, NC
Background/Purpose: Faulty synthesis of information due to Cognitive Errors (CEs) is the most common cause of incorrect medical decision making. Medical education often focuses on…
Abstract Number: 1098 • ACR Convergence 2022
Perceived Barriers and Opportunities to Accessing Rheumatoid Arthritis Care on Navajo Nation: The Primary Care Providers’ Perspectives
Jennifer Mandal¹, Catherine Nasrallah², Tabitha Carroway³, Mary Margaretten³, Gwendolyn Grant⁴ and Jinoos Yazdany³, ¹University of California San Francisco, San Francisco, CA, ²UCSF, San Francisco, ³UCSF, San Francisco, CA, ⁴Centura Health, Durango, CO
Background/Purpose: Navajo Nation is the largest American Indian reservation, home to 250,000 tribal members living on 27,000 square miles. The prevalence of RA among the…
Abstract Number: 1097 • ACR Convergence 2022
Intrinsic STAT1 Deficiency Underlies Proinflammatory Imprint of Naive CD4+ T Cells in Spondyloarthritis
Bilade CHERQAOUI¹, Frederic Cremazy¹, Marc Lauraine¹, Ghazal Shammas², Roula Said-Nahal³, Hendrick Mambu Mambueni⁴, Felicie Costantino², Marine Fourmont², Simon Glatigny², Luiza Maria Araujo² and Maxime Breban², ¹INSERM U1173, UFR Simone Veil, Versailles-Saint Quentin / Paris-Saclay University, Montigny-le-Bretonneux, France, ²1INSERM U1173, UFR Simone Veil, Versailles-Saint Quentin / Paris-Saclay University, Montigny-le-Bretonneux, France, ³Rheumatology Division - Ambroise Pare Hospital, APHP, Boulogne-Billancourt, France, ⁴Genomic Platform of Faculty of Health Simone Veil - UVSQ university, Montigny-le-Bretonneux, France
Background/Purpose: Spondyloarthritis (SpA) development is associated with type 3 immune response activation. In HLA-B27/human β2-microglobulin transgenic rat model (B27-rat), this might at least be related…
Abstract Number: 1109 • ACR Convergence 2022
High Interleukin-13 Level Is Associated with Disease Stability in Interstitial Lung Disease
Elena Joerns¹, David Karp¹, Jeffrey Sparks², Traci Adams¹, Una Makris³ and Chad Newton¹, ¹UT Southwestern, Dallas, TX, ²Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ³UT Southwestern Medical Center and Dallas VA, Dallas, TX
Background/Purpose: Interstitial lung disease (ILD) is a disease of lung parenchyma manifesting with inflammation and fibrosis. Interstitial lung disease (ILD) is a frequent complication of…
Abstract Number: 1110 • ACR Convergence 2022
Solving Sarcoidosis: A Transcriptome-based Meta-analysis of Clinical Sarcoidosis Studies Illustrates Shared Pathophysiology, Identifies Candidate Biomarkers and Suggests a Therapeutic Mechanism of JAK Inhibition
Ingrid Lindquist¹, James T. Rosenbaum² and Marcia Friedman³, ¹Oregon Health and Science University, Portland, OR, ²Legacy Devers Eye Institute, Portland, OR, ³Oregon Health and Science University, Division of Arthritis and Rheumatic Diseases, Portland, OR
Background/Purpose: Sarcoidosis is a systemic, non-caseating granulomatous disease driven by a dysregulated immune response to environmental antigens. A wide range of clinical manifestations coupled with…
Abstract Number: 1100 • ACR Convergence 2022
Racial Differences in Clinical Trial Perceptions Among a Large, Predominantly Black Cohort of Patients with Systemic Lupus Erythematosus in the Southeastern United States
Jessica Williams¹, Gaobin Bao¹, Charmayne Dunlop-Thomas², Cristina Drenkard², Kim Schofield¹ and S. Sam Lim², ¹Emory University School of Medicine, Atlanta, GA, ²Emory University, Atlanta, GA
Background/Purpose: Black patients have higher incidence and severity of systemic lupus erythematosus (SLE) and worse outcomes as compared to White patients, yet Black patients are…
Abstract Number: 1108 • ACR Convergence 2022
Abnormal Baseline Chest CT Shows Increased Risk for Immune Checkpoint Inhibitor Associated Pneumonitis
Danielle Stahlbaum¹, Renea Jablonski¹, Mary Strek² and Pankti Reid¹, ¹University of Chicago Medical Center, Chicago, IL, ²University of Chicago, Chicago, IL
Background/Purpose: Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy but can result in off-target toxicities known as immune-related adverse events (irAEs). With increased use of…
Abstract Number: 1121 • ACR Convergence 2022
Intricate Roles of Low Gene Copy Numbers for Complement C4, C4A Deficiency and HLA-DRB1*03 as Genetic Risk Factors for Myositis, Its Subgroups and Autoantibodies
Danlei Zhou¹, Emily H King¹, Simon Rothwell², Olga Kryštůfková³, Antonella Notarnicola⁴, Samantha Coss¹, Rabheh Abdul Aziz⁵, Katherine E Miller¹, Amanda Dang¹, G. Richard Yu¹, Joanne Drew⁶, Emeli Lundstrom⁴, Lauren Pachman⁷, Gulnara Mamyrova⁸, Rodolfo V Curiel⁸, Boel De Paepe⁹, Jan De Bleecker⁹, Antony Payton¹⁰, William Ollier¹¹, Terrance P O'Hanlon¹², Ira Targoff¹², Willy Flegel¹², Vidya Sivaraman⁶, Edward Oberle⁶, Shoghik Akoghlanian⁶, Kyla Driest⁶, Charles H Spencer¹³, Yee Ling Wu¹⁴, Haikady N Nagaraja¹⁵, Stacy P Ardoin⁶, Hector Chinoy¹⁶, Lisa G Rider¹², Frederick Miller¹², Ingrid Lundberg¹⁷, Leonid Padyukov¹⁸, Jiří Vencovský³, Janine A Lamb² and Chack-Yung Yu¹, ¹Center for Microbial Pathogenesis, Abigail Wexner Research Institute, Nationwide Children’s Hospital, Columbus, OH, ²National Institute for Health Research Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, The University of Manchester, Manchester, United Kingdom, ³Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, ⁴Division of Rheumatology, Department of Medicine, Solna, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, ⁵Division of Rheumatology, Nationwide Children’s Hospital and Department of Pediatrics, The Ohio State University, Columbus, OH, ⁶Division of Rheumatology, Nationwide Children's Hospital and Department of Pediatrics, The Ohio State University, Columbus, OH, ⁷Northwestern's Feinberg School of Medicine. Ann and Robert H. Lurie Children's Hospital of Chicago; Stanley Manne Children's Research Institute of Chicago, Lake Forest, IL, ⁸Division of Rheumatology, Department of Medicine, George Washington University School of Medicine and Health Sciences, Washington, DC, ⁹Department of Neurology, Ghent University Hospital, Ghent, Belgium, ¹⁰Division of Informatics, Imaging and Data Sciences, School of Health Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, United Kingdom, ¹¹Faculty of Science and Engineering, Manchester Metropolitan University, Manchester, United Kingdom, ¹²Environmental Autoimmunity Group, Clinical Research Branch, National Institute of Environmental Health Sciences (NIEHS), National Institutes of Health, Bethesda, MD, ¹³Division of Rheumatology, Nationwide Children’s Hospital and Department of Pediatrics, The Ohio State University, Columbus, MS, ¹⁴Department of Microbiology and Immunology, Loyola University Chicago, Maywood, IL, ¹⁵Division of Biostatistics, The Ohio State University, Columbus, OH, ¹⁶The University of Manchester, Sale, United Kingdom, ¹⁷Karolinska Universitetssjukhuset, Karolinska Institutet, Stockholm, Sweden, ¹⁸Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are a group of autoimmune diseases characterized by autoantibodies plus infiltration of leukocytes into muscles and/or the skin, leading to…
Abstract Number: 1115 • ACR Convergence 2022
Medication Co-pay Modifies Treatment Adherence in Patients with Systemic Lupus Erythematosus
Raisa Lomanto Silva¹, Gretchen M Swabe² and Jared W Magnani³, ¹University of Pittsburgh Medical Center, Pittsburgh, PA, ²Division of Cardiology, University of Pittsburgh School of Medicine, Pittsburgh, PA, ³Heart and Vascular Institute, University of Pittsburgh Medical Center; Division of Cardiology, University of Pittsburgh School of Medicine, Pittsburgh, PA
Background/Purpose: Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease with significant morbidity and mortality. Adherence to SLE medications is challenging and estimated as 30-80%…
Abstract Number: 1117 • ACR Convergence 2022
Efficacy and Safety of Deucravacitinib, an Oral, Selective, Allosteric TYK2 Inhibitor, in Patients with Active Systemic Lupus Erythematosus: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study
Marilyn Pike¹, Joan Merrill², Eric Morand³, Ronald van Vollenhoven⁴, Victoria Werth⁵, Coburn Hobar⁶, Nikolay Delev⁶, Vaishali Shah⁷, Brian Sharkey⁶, Thomas Wegman⁶, Ian M. Catlett⁶, Subhashis Banerjee⁶ and Shalabh Singhal⁶, ¹MedPharm Consulting Inc., Raleigh, NC, ²Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Monash University, Victoria; Department of Rheumatology, Monash Health, Melbourne, Australia, ⁴Amsterdam University Medical Centers, Amsterdam, Netherlands, ⁵University of Pennsylvania, Philadelphia, PA, ⁶Bristol Myers Squibb, Princeton, NJ, ⁷Bristol Myers Squibb, Robbinsville, NJ
Background/Purpose: Tyrosine kinase 2 (TYK2) mediates signaling of Type I IFNs, IL-23, and IL-12, key cytokines involved in lupus pathogenesis. Deucravacitinib (DEUC) is an oral,…
Abstract Number: 1113 • ACR Convergence 2022
Remibrutinib (LOU064) in Sjögren’s Syndrome: Safety and Efficacy Results from a 24‑Week Placebo-controlled Proof-of-Concept Study
Thomas Dörner¹, Antónia Szántó², Jui-Cheng Tseng³, Martin Kaul⁴, Ilona Pylvaenaeinen⁵, Malika Hanser⁶, Nasri Abdallah⁶, Bruno Cenni⁶ and Richard Siegel⁶, ¹Department of Rheumatology and Clinical Immunology, Charité Universitätsmedizin Berlin, Berlin, Germany, ²Debreceni Egyetem Klinikai Centrum, Debrecen, Hungary, ³Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan, ⁴Independent Consultant, Neustadt, Germany, ⁵Early Development Analytics, Novartis Pharmaceutical AG, Basel, Switzerland, ⁶Novartis Institutes for BioMedical Research, Basel, Switzerland
Background/Purpose: Sjögren's syndrome (SS) is a systemic autoimmune disease of unknown etiology characterized by B-cell hyperactivation, lymphoid infiltration, progressive destruction of exocrine glands, and various…
Abstract Number: 1123 • ACR Convergence 2022
Excess of Rare Deleterious Variants Within JAK-STAT Pathway – Related Genes in Patients with Rheumatoid Arthritis Associated Interstitial Lung Disease
Pierre-Antoine Juge¹, Steven Gazal², Raphaël Borie³, Lidwine Wemeau⁴, Marie-Pierre Debray⁵, Sebastien Ottaviani⁶, Sylvain Marchand Adam⁷, Christophe Richez⁸, Hilario Nunes⁹, Pascal Richette¹⁰, Caroline Kannengiesser¹¹, Jérome Avouac¹², Jean Sibilia¹³, René-Marc Flipo¹⁴, Vincent Cottin¹⁵, Thierry Schaeverbeke¹⁶, Martin Soubrier¹⁷, Nathalie Saidenberg-Kermanac’h¹⁸, Dominique Valeyre¹⁹, Catherine Boileau¹¹, Bruno Crestani²⁰ and Philippe Dieude²¹, ¹Rheumatology department, Bichat Hospital, Paris, France, ²University of Southern California, Los Angeles, CA, ³Pulmonology department, Bichat Hospital, Paris, France, ⁴Pulmonology department, Lille University hospital, Lille, France, ⁵Radiology department, Hôpital Bichat, Paris, France, ⁶Hopital Bichat-Claude Bernard, Paris, France, ⁷Pulmonology department, Tours University Hospital, Tours, France, ⁸Université de Bordeaux, Bordeaux, France, ⁹Pulmonology department, Hopital Avicenne, Bobigny, France, ¹⁰Department of Rheumatology, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, Paris, France, ¹¹Genetic Department, Bichat hospital, Paris, France, ¹²Rheumatology Department, Cochin hospital, Paris, France, ¹³University Hospital of Strasbourg, Strasbourg, France, ¹⁴Hôpital Roger Salengro, Lille, France, ¹⁵Coordinating Reference Center for Rare Pulmonary Diseases, Louis Pradel Hospital, University of Lyon, INRAE, Lyon, France, ¹⁶FHU ACRONIM, University Hospital of Bordeaux, University of Bordeaux, Bordeaux, France, ¹⁷Gabriel-Montpied Hospital, Clermont-Ferrand, France, ¹⁸Rheumatology Department, Avicenne Hospital, Bobigny, France, ¹⁹Pulmonology department, Avicenne Hospital, Bobigny, France, ²⁰Hopital Bichat, Paris University, Paris, France, ²¹Université Paris Cité, Paris, France
Background/Purpose: Interstitial lung disease (ILD) is a leading cause of morbidity and mortality in patients with RA. To date, there are no specific treatments available…
Abstract Number: 1067 • ACR Convergence 2022
Analysis of the Transcriptomic Profiles of Rheumatic Skin Diseases Reveals Disease-specific Endotypes
Sneha Shrotri¹, Kathryn Kingsmore Allison¹, Prathyusha Bachali², Amrie Grammer³ and Peter Lipsky¹, ¹AMPEL BioSolutions, Charlottesville, VA, ²AMPEL BioSolutions, Redmond, WA, ³AMPEL LLC, Charlottesville, VA
Background/Purpose: Patients with rheumatic skin diseases such as cutaneous lupus erythematosus (CLE) and systemic sclerosis (SSc) can be classified from individuals with healthy skin using…
Abstract Number: 1017 • ACR Convergence 2022
Minimal Important Difference (MID), Minimal Detectable Change (MDC), and Disease Activity Thresholds for Two Novel Composite Instruments (3VAS, 4VAS) in Patients with Psoriatic Arthritis: Pooled Analysis of Three Phase 3 Studies
William Tillett¹, Laura Coates², Marijn Vis³, Joseph Merola⁴, Enrique R Soriano⁵, Michelle Perate⁶, May Shawi⁷, Miriam Zimmermann⁸, Emmanouil Rampakakis⁹, Mohamed Sharaf¹⁰, Peter Nash¹¹ and Philip Helliwell¹², ¹Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ²Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK, Oxford, England, United Kingdom, ³Erasmus MC Universitair Medisch Centrum, Rotterdam, Netherlands, ⁴Harvard Medical School, Brigham and Women's Hospital, Boston, MA, ⁵Rheumatology Unit and University Institute, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁶Janssen Scientific Affairs, LLC, Horsham, PA, ⁷Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA, ⁸Immunology, Janssen Scientific Affairs, LLC, Zug, Switzerland, ⁹McGill University, Department of Pediatrics and JSS Medical Research, Montréal, QC, Canada, ¹⁰Johnson & Johnson, Middle East FZ LLC, Dubai, United Arab Emirates, ¹¹School of Medicine, Griffith University, Sunshine Coast, Australia, ¹²Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom
Background/Purpose: Though continuous composite measures of disease activity for psoriatic arthritis (PsA) assessment exist, abbreviated measures that are more feasible for screening in routine clinical…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].